-
公开(公告)号:US5824552A
公开(公告)日:1998-10-20
申请号:US693291
申请日:1996-08-15
申请人: Yoshiharu Takazawa , Takami Arai , Masamichi Motoki , Kenji Nagura , Seiichi Yokoyama , Yoshinobu Miyatsu , Hiroshi Mizokami
发明人: Yoshiharu Takazawa , Takami Arai , Masamichi Motoki , Kenji Nagura , Seiichi Yokoyama , Yoshinobu Miyatsu , Hiroshi Mizokami
CPC分类号: C12N9/6464 , C12N5/0018 , C12Y304/21069 , C12N2501/999
摘要: A method is disclosed for culturing animal cells in a medium characterized n that said medium contains a compound represented by the general formula ##STR1## wherein, R denotes COOM or CHO, herein M denotes hydrogen, an alkali metal or a C.sub.1 to C.sub.3 alkyl group, and n is an integer of 1 to 3. According to the present method, proliferation of animal cells can be enhanced with good reproducibility.
摘要翻译: PCT No.PCT / JP95 / 00113 Sec。 371日期:1996年8月15日 102(e)日期1996年8月15日PCT 1995年1月30日PCT PCT。 第WO95 / 22599号公报 日期:1995年8月24日公开了用于在培养基中培养动物细胞的方法,其特征在于所述培养基含有由通式(I)表示的化合物,其中R表示COOM或CHO,其中M表示氢,碱 金属或C1〜C3烷基,n为1〜3的整数。根据本方法,能够以良好的再现性提高动物细胞的增殖。
-
公开(公告)号:US5443968A
公开(公告)日:1995-08-22
申请号:US170361
申请日:1994-01-03
CPC分类号: C12N9/6464 , C12P21/02 , C12Y304/21069 , A61K38/00
摘要: In a process of production of a useful protein by culturing a human embryonal kidney cell-derived 293 strain which is introduced with a useful protein-expressing gene, it becomes possible to obtain a culture fluid containing the useful protein in a high concentration using an extremely small amount of the medium, by carrying out a fed-batch culture and adding a sugar or a sugar and a calcium in a specified stage of the culture.
摘要翻译: PCT No.PCT / JP93 / 00586 Sec。 371日期1994年1月3日 102(e)日期1994年1月3日PCT 1993年4月30日PCT PCT。 公开号WO93 / 22448 日期:11月11日。在通过培养引入了有用的蛋白质表达基因的人胚肾细胞来源的293菌株生产有用蛋白质的过程中,可以获得含有有用蛋白质的培养液 通过进行补料分批培养并在培养的指定阶段加入糖或糖和钙,以高浓度使用极少量的培养基。
-
公开(公告)号:US06706745B1
公开(公告)日:2004-03-16
申请号:US09554799
申请日:2000-05-18
申请人: Takayuki Hara , Tomohisa Nakada , Yasunobu Takano , Satoshi Sugiura , Takaharu Tsutsumi , Yoshiharu Takazawa , Reiko Takarada
发明人: Takayuki Hara , Tomohisa Nakada , Yasunobu Takano , Satoshi Sugiura , Takaharu Tsutsumi , Yoshiharu Takazawa , Reiko Takarada
IPC分类号: A61K31425
CPC分类号: C07D207/08 , C07C251/18 , C07C257/18 , C07C2601/14 , C07D207/09 , C07D207/16 , C07D211/22 , C07D211/26 , C07D211/28 , C07D211/40 , C07D211/62
摘要: The present invention relates to a biphenylamidine derivative of the general formula (1): or a pharmaceutically acceptable salt thereof, which is a novel compound functioning as a clinically applicable FXa inhibitor.
摘要翻译: 本发明涉及通式(1)的联苯基脒衍生物或其药学上可接受的盐,它是作为临床适用的FXa抑制剂起作用的新化合物。
-
公开(公告)号:US06348478B1
公开(公告)日:2002-02-19
申请号:US09554449
申请日:2000-05-15
申请人: Takayuki Hara , Tomohisa Nakada , Yasunobu Takano , Satoshi Sugiura , Takaharu Tsutsumi , Yoshiharu Takazawa , Reiko Takarada
发明人: Takayuki Hara , Tomohisa Nakada , Yasunobu Takano , Satoshi Sugiura , Takaharu Tsutsumi , Yoshiharu Takazawa , Reiko Takarada
IPC分类号: C07D21355
CPC分类号: C07D213/64 , C07C257/18 , C07C2602/46 , C07D209/08 , C07D209/44 , C07D213/65 , C07D213/68 , C07D213/73
摘要: The present invention is a biphenylamidine derivative represented by the formula (1) or a pharmaceutically acceptable derivative thereof: and the biphenylamidine derivative or the pharmaceutically acceptable derivative thereof is a novel compound which can be used as a clinically applicable FXa inhibitor.
摘要翻译: 本发明是由式(1)表示的联苯基脒衍生物或其药学上可接受的衍生物:联苯基脒衍生物或其药学上可接受的衍生物是可用作临床适用的FXa抑制剂的新型化合物。
-
公开(公告)号:US5219752A
公开(公告)日:1993-06-15
申请号:US730386
申请日:1991-07-15
CPC分类号: C12N5/0037 , C12N2500/14 , C12N2500/25
摘要: Adherent 293 human kidney cells are continuously cultured in suspension in serum-free medium. Fresh medium is fed into a culture vessel and spent medium is withdrawn from the vessel. The 293 cells are maintained in small aggregates in suspension at a density of at least 3.times.10.sup.6 cells/ml for 30 days. The formation of large cell clumps is prevented by maintaining the concentration of calcium in the serum-free medium at 0.002 mM to 0.3 mM.
摘要翻译: 将粘附的293人肾细胞在悬浮液中连续培养于无血清培养基中。 将新鲜培养基加入到培养容器中,并从容器中取出废培养基。 将293细胞以至少3×10 6细胞/ ml的密度悬浮保持在悬浮液中的小聚集体30天。 通过将无血清培养基中的钙浓度维持在0.002mM至0.3mM来防止大细胞团的形成。
-
-
-
-